Published in Vaccine Weekly, August 16th, 2006
According to researchers in the United States, "We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rA1s3p-N, induces a broader antibody response than rA1s1p-N and a similar cell-mediated immune response."
"The rA1s3p-N vaccine was equally as effective as rA1s1p-N against disseminated candidiasis but was more effective than rAls1p-N against oropharyngeal or vaginal candidiasis," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-08-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.